Abstract: This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.

Abstract: There is described herein a method for specifically detecting Babesia species nucleic acid in a sample, which in one aspect comprises: (1) contacting a sample, said sample suspected of containing Babesia species nucleic acid, with at least two oligomers for amplifying a target region of a Babesia species target nucleic acid, wherein the at least two amplification oligomers comprise: (a) a first amplification oligomer comprising a first target-hybridizing sequence (i) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:66 and comprises SEQ ID NO:56 or 57; or (ii) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:96 and comprises SEQ ID NO:101; or (iii) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:97 and comprises SEQ ID NO:101; (iv) comprises or consists of SEQ ID NO:8; (v) comprises or consists of SEQ ID NO:83 and (b) a second am

Abstract: The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.

Abstract: The present invention relates to new methods for diagnosing a pregnancy-associated disorder by analyzing fetal DNA present in the mother's blood. More specifically, this invention relies on the discovery that the maspin gene is differentially methylated in fetal DNA and in maternal DNA and provides these new diagnostic methods, which distinguish fetal DNA from maternal DNA and detect prenatal disorders based on abnormalities in fetal DNA level and methylation status.

Abstract: Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids.

Abstract: Methods for the rapid detection of the presence or absence of Mycoplasma genitalium (MG) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers, probes targeting the target MG gene, along with kits are provided that are designed for the detection of MG.

Abstract: A system for extracting analytes from a biological sample, which includes: an electronic pipette having pipette cones with a tip; a well support; a pipette holder including: a base which can removably house each well support; a pipette support into which the pipette is inserted, and which can move relative to the base between a first position in which the tips of the cones are inserted in a well of the support and at least one second position in which the tips are outside the wells; a housing facing the pipette cones above their tip when the pipette support is in the first position, and facing the tips of the pipette cones when the pipette support is in the second position; and a magnetized part removably inserted in the housing.

Abstract: Methods of identifying canine subjects having an increased likelihood of developing elevated levels of 4-ethylphenyl sulfate, canine stress, canine anxiety and/or an inhibition of growth of beneficial microbes and promotion of growth of harmful microbes are disclosed. Methods comprise analyzing a biological sample obtained from the canine subject for the presence of two copies of a minor allele of the single nucleotide polymorphism BICF2P1175095 in a canine subject. Methods of treating the identified canine subjects by administering an effective amount of tomato pomace are also disclosed. Methods of treating canine subjects for elevated 4-EPS levels, canine anxiety or canine stress are disclosed. Canine food compositions that comprises tomato pomace are disclosed.

Abstract: Methods of analyzing a biological sample obtained from the canine subject for the presence of one or two copies one or two copies of minor allele T of SNP Affx-206229307; or one or two copies of minor allele A of SNP Affx-206560187; or one or two copies of minor allele T of SNP Affx-206229307 and one or two copies of minor allele A of SNP Affx-206560187 are disclosed. The methods are used in methods to identify a canine subject that has an increased likelihood or risk of hypothyroidism and in methods of treating a canine subject to reduce risk of hypothyroidism or to treat a canine subject that has hypothyroidism. The treatments comprise administering to the canine subject a low arginine diet and/or comprising an effective amount of a composition comprising a protein source, a carbohydrate source, a vegetable source, and a fruit source. Canine food compositions are disclosed.

Abstract: A method of detecting a presence of Francisella tularensis (F. tularensis). The method includes amplifying a first nucleic acid from said specimen using a first plurality of primers, said first plurality of primers comprising SEQ ID NO 4 and SEQ ID NO 5. When the first nucleic acid is detected, then the presence of F. tularensis is determined.

Abstract: A polynucleotide comprising a hybrid nucleotide sequence representative of a deletional mutation of the GYPB gene, wherein the hybrid nucleotide sequence representative of a deletional mutation of the GYPB gene has a sequence according to SEQ ID NO 1 or SEQ ID NO 2, or a complementary sequence thereto.

Abstract: Provided herein is technology for colorectal neoplasia screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of colorectal neoplasia in 1) individuals at, older or younger than 50 years of age, or 2) individuals having Lynch Syndrome.

Abstract: Specific single nucleotide polymorphisms (SNPs) in the human genome, and their association with deep vein thrombosis (DVT) and related pathologies, such as pulmonary embolism (PE).

Abstract: The recently developed liquid-based Papanicolaou (Pap) smear allows not only cytologic evaluation but also collection of DNA for detection of HPV, the causative agent of cervical cancer. We tested these samples to detect somatic mutations present in rare tumor cells that might accumulate in the cervix once shed from endometrial and ovarian cancers. A panel of commonly mutated genes in endometrial and ovarian cancers was assembled and used to identify mutations in all 46 endometrial or cervical cancer tissue samples. We were able also able to identify the same mutations in the DNA from liquid Pap smears in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). We developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear without prior knowledge of the tumor's genotype.

Abstract: Methods of identifying polymorphisms associated with ataxia-ocular apraxia 2 (AOA2), are described. The polymorphisms associated with AOA2 include specific mutations in the senataxin (SETX) gene. Also described are methods of diagnosis of AOA2, as well as methods of assessing an individual for carrier status for AOA2.

Abstract: The present application relates to detection units and methods for detecting one or more target analytes in a sample using a complex formed by a target and first and second probes, wherein the complex comprises an elongated region, a particle that is coupled to the first probe, and a solid support that is coupled to the second probe. Specific binding of a target analyte can be distinguished from non-specific binding of the particle by measuring the displacement of the particle.

Abstract: A method of detecting a nucleic acid including a) mixing a solution containing a carboxylic acid and/or a salt thereof, a cerium oxide support and a sample containing a nucleic acid to adsorb said nucleic acid to said cerium oxide support, b) separating said cerium oxide support on which said nucleic acid was adsorbed from the mixture obtained in a), c) collecting said nucleic acid by adding an eluent to said cerium oxide support on which said nucleic acid was adsorbed and separated in b), and d) detecting said nucleic acid collected in c) by a hybridization reaction or a nucleic acid amplification reaction.

Abstract: Methods for determining the presence or absence of expansion of CGG repeat sequence in the FMR1 gene presence or absence of expansion of CCG repeat sequence in the FMR2 gene are provided. The methods are useful in identifying an individual with normal/intermediate, versus premutation or full mutation allele of FMR1 gene and FMR2 gene due to the expansion of CGG repeats and CCG repeats in the 5?-untranslated region respectively. The methods are also useful for screening newborns for fragile X syndrome or for screening women to determine heterozygosity status with full premutation of the CCG repeat tract. The methods are also useful in estimating the premutation and full mutation carrier frequency and estimating the prevalence of FXTAS AND FXPOI in a population. The methods are simple, rapid and require small amount of sample.

Abstract: A panel of gene expression markers for gastric cancer patient treated or to be treated by cetuximab is provided. Methods and compositions are also provided, e.g., kits, for evaluating gene expression levels of the markers and methods of using such gene expression levels to predict a gastric cancer patient's response to cetuximab.

Abstract: Disclosures herein encompass methods of treating a subject with moderate to severe hidradenitis suppurativa (HS) encompassing the determination of differential gene expression to characterize HS severity followed by administration of a treatment specific for the stage of HS severity characterized in the subject.